CFO interim
TransCode Therapeutics, Inc. names John Tattory interim CFO
TransCode Therapeutics, Inc. reported in a Form 8-K filed September 11, 2026 that John Tattory was named interim Interim Chief Financial Officer, principal financial officer and principal accounting officer, effective September 9, 2026.
In the filing's words
John Tattory was appointed to serve as the Company’s Interim Chief Financial Officer, principal financial officer and principal accounting officer, effective as of September 9, 2026. Beginning September 9, 2026, Mr. Tattory will provide his services as a consultant through Stout Risius Ross, LLC (“Stout”) at an agreed upon hourly rate.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | TransCode Therapeutics, Inc. (RNAZ) |
|---|---|
| Event | Interim |
| Incoming | John Tattory |
| Outgoing | Thomas A. Fitzgerald, M.B.A. |
| Title in the filing | Interim Chief Financial Officer, principal financial officer and principal accounting officer |
| Effective | September 9, 2026 |
| 8-K filed | September 11, 2026 |
| Internal promotion | Not established by the source |
| SEC CIK | 0001829635 |
TransCode Therapeutics, Inc. reported this change in a Form 8-K, Item 5.02, filed September 11, 2026. The filing's own words are quoted above.
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about John Tattory? Send a correction with the primary source.